Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50–75 Years of Age with Advanced Myelodysplastic Syndrome

Investigators conducted a multicenter biologic assignment trial comparing reduced-intensity hematopoietic cell transplantation to hypomethylating therapy or best supportive care in subjects 50-75 years of age with intermediate-2 or high-risk de novo myelodysplastic syndromes.
[Journal of Clinical Oncology]
Full Article
Bookmark

No account yet? Register

0
Share

Cryopreservation of Unrelated Donor Hematopoietic Stem Cells: The Right Answer for Transplantations during the COVID-19 Pandemic?

Investigators compared 32 patients who underwent unrelated donor (UD) hematopoietic stem cell transplantation (HSCT) using cryopreserved peripheral blood stem cells (PBSC) during the COVID-19 pandemic with 32 patients who underwent UD HSCT using fresh PBSC in the previous period.
[Bone Marrow Transplantation]
Full Article
Bookmark

No account yet? Register

0
Share

60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy

The authors review the historical basis underpinning the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) as well as advances in knowledge obtained by defining mechanisms of allo-HSCT activity.
[Cancer Research]
Abstract
Bookmark

No account yet? Register

0
Share

Human Endometrium-Derived Stem Cell Improves Cardiac Function after Myocardial Ischemic Injury by Enhancing Angiogenesis and Myocardial Metabolism

Investigators investigated whether human endometrium-derived stem cells could be used for cardiac repair after ischemic injury and their possible underlying mechanisms.
[Current Stem Cell Research & Therapy]
Fan, X., He, S., Song, H., Yin, W., Zhang, J., Peng, Z., Yang, K., Zhai, X., Zhao, L., Gong, H., Ping, Y., Jiao, X., Zhang, S., Yan, C., Wang, H., Li, R.-K., & Xie, J. (2021). Human endometrium-derived stem cell improves cardiac function after myocardial ischemic injury by enhancing angiogenesis and myocardial metabolism. Stem Cell Research & Therapy, 12(1), 344. https://doi.org/10.1186/s13287-021-02423-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Emerging Understanding of Apoptosis in Mediating Mesenchymal Stem Cell Therapy

Investigators summarize the emerging understanding of apoptosis in mediating mesenchymal stem cell transplant, highlighting the potential of apoptotic extracellular vesicles as cell-free therapeutics.
[Cell Death & Disease]
Fu, Y., Sui, B., Xiang, L., Yan, X., Wu, D., Shi, S., & Hu, X. (2021). Emerging understanding of apoptosis in mediating mesenchymal stem cell therapy. Cell Death & Disease, 12(6), 1–12. https://doi.org/10.1038/s41419-021-03883-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase I Study in Patients with Advanced Parkinson’s Disease

BlueRock Therapeutics announced the dose administration for the first patient in a Phase I, open-label study of PSC-derived dopaminergic neurons in patients with advanced Parkinson’s disease.
[BlueRock Therapeutics]
Press Release
Bookmark

No account yet? Register

0
Share

Prognostic Value of Measurable Residual Disease Monitoring by Next-Generation Sequencing before and after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

The authors collected samples before and after allogeneic hematopoietic stem cell transplantation from two independent prospective cohorts and investigated the prognostic impact of amplicon-based next-generation sequencing-based assessment.
[Blood Cancer Journal]
Kim, H.-J., Kim, Y., Kang, D., Kim, H. S., Lee, J.-M., Kim, M., & Cho, B.-S. (2021). Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Blood Cancer Journal, 11(6), 1–11. https://doi.org/10.1038/s41408-021-00500-9 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Human-Induced Neural and Mesenchymal Stem Cell Therapy Combined with a Curcumin Nanoconjugate as a Spinal Cord Injury Treatment

Researchers report on the development of an enhanced synergistic combination therapy comprising polyacetal–curcumin nanoconjugate and neural stem cells derived from induced pluripotent stem cells + mesenchymal stem cells treatment as a treatment option for severe sub-acute traumatic spinal cord injury.
[International Journal of Molecular Sciences]
Full Article
Bookmark

No account yet? Register

0
Share

Heartseed and Novo Nordisk Enter into Global Collaboration and Licence Agreement for Stem Cell-Based Therapy for Heart Failure

Heartseed Inc. and Novo Nordisk A/S announced that they have entered into a collaboration and licence agreement for the development, manufacturing and commercialisation of Heartseed’s asset HS-001, an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells, which is currently under development by Heartseed for the treatment of heart failure.
[Heartseed, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Role of CXCR4 in the Progression and Therapy of Acute Leukemia

The authors summarize the role of CXCR4 in progression and treatment of acute leukemia, and discuss the potential value of using CXCR4 antagonists as immunosensitizer for graft-vs-leukemia effects of allogeneic HSC transplantation.
[Cell Proliferation]
Hayat, H., Hayat, H., Dwan, B. F., Gudi, M., Bishop, J. O., & Wang, P. (2021). <p>A Concise Review: The Role of Stem Cells in Cancer Progression and Therapy</p>. OncoTargets and Therapy, 14, 2761–2772. https://doi.org/10.2147/OTT.S260391 Cite
Full Article
Bookmark

No account yet? Register

0
Share

COVID-19 and Stem Cell Transplantation; Results from an EBMT and GETH Multicenter Prospective Survey

The authors reported on 382 COVID-19 patients having undergone allogeneic or autologous hematopoietic cell transplantation reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH).
[Leukemia]
Full Article
Bookmark

No account yet? Register

0
Share
Share